1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: NORVASC (Amlodipine besylate) Oral Drops

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>NORVASC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product used as Antianginal; antihypertensive</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: Light yellow solution

Additional Hazard Information:
- Short Term: May be harmful if swallowed. May cause eye irritation (based on components).
- Antihypertensive drug: has blood pressure-lowering properties

Known Clinical Effects:
- Ingestion of this material may cause effects similar to those seen in clinical use including abdominal pain, dizziness, flushing, heart palpitations, and swelling.
- EU Indication of danger: Dangerous for the Environment

Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

| Ingredient        | CAS Number | EU EINECS/ELINCS List | EU Classification | % 
|-------------------|------------|------------------------|--------------------|------
| Amlodipine besylate | 111470-99-6 | Not Listed             | N;R50/53           | 1.5 
|                   |            |                        | Xn;R22             |      
|                   |            |                        | Xi;R41             |      
| Propylene glycol  | 57-55-6    | 200-338-0              | Not Listed         | *    

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides, hydrogen chloride and other chlorine- and sulfur-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Use caution in approaching fire.

Fire / Explosion Hazards: Not determined

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize generating airborne mists and vapors. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Amlodipine besylate
- Pfizer OEL TWA-8 Hr: 100µg/m³

Propylene glycol
- Australia TWA: 150 ppm, 474 mg/m³, 10 mg/m³
- Ireland OEL - TWAs: 150 ppm, 470 mg/m³, 10 mg/m³
- Latvia OEL - TWA: 7 mg/m³
- Lithuania OEL - TWA: 7 mg/m³


Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Solution</th>
<th>Color:</th>
<th>Light yellow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>Odorless</td>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Molecular Weight:</td>
<td>Mixture</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Amlodipine besylate
- Rat (M) Oral LD50 393 mg/kg
- Rat (F) Oral LD50 686 mg/kg

Propylene glycol
- Mouse Oral LD50 22,000 mg/kg
- Rat Oral LD50 20,000 mg/kg
- Rabbit Dermal LD50 20,800 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Amlodipine besylate
- Eye Irritation Rabbit Severe
- Skin Irritation Rabbit Non-irritating
- Skin Sensitization - GPMT Guinea Pig Negative

Propylene glycol
- Skin Irritation Rabbit Mild
- Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Amlodipine besylate
- 3 Month(s) Rat Oral 3 mg/kg/day NOAEL Adrenal gland, Heart
- 1 Month(s) Rat Oral 3.5 mg/kg/day LOEL Heart
- 1 Year(s) Rat Oral 2 mg/kg/day NOAEL Adrenal gland, Heart
11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Amlodipine besylate**
- Fertility and Embryonic Development: Rat Oral 25 mg/kg/day NOAEL Not teratogenic, Maternal toxicity
- Peri-/Postnatal Development: Rat Oral 4 mg/kg/day NOAEL Fetotoxicity, Fetal mortality
- Prenatal & Postnatal Development: Rat Oral 25 mg/kg/day NOAEL Not Teratogenic
- Prenatal & Postnatal Development: Rabbit Oral 25 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**Amlodipine besylate**
- *In Vitro* Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
- *In Vivo* Cytogenetics: Mouse Bone Marrow Negative
- *In Vitro* Chromosome Aberration Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Amlodipine besylate**
- 24 Month(s): Rat Oral, in feed 2.5 mg/kg/day NOAEL Not carcinogenic, No effects at maximum dose
- 24 Month(s): Mouse Oral, in feed 0.5 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. The active ingredient in this formulation may be harmful to aquatic organisms. Releases to the environment should be avoided. See aquatic toxicity data, below:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

**Amlodipine besylate**
- *Daphnia magna* (Water Flea) OECD EC50 48 Hours 9.9 mg/L
- *Oncorhynchus mykiss* (Rainbow Trout) OECD LC50 96 Hours 14 mg/L
- Green algae OECD EbC50 72 Hours 0.28 mg/L
- Green Algae OECD ErC50 72 Hours > 0.91 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

**Amlodipine besylate**
- *Nostoc sp.* (Freshwater Cyanobacteria) MIC 20 mg/L
- *Aspergillus Niger* MIC > 100 mg/L
- *Trichoderma viride* MIC > 100 mg/L
- *Clostridium perfingens* MIC > 100 mg/L
  - *Bacillus subtilis* MIC 80 mg/L
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Dangerous for the Environment

EU Risk Phrases: R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

EU Safety Phrases: S57 - Use appropriate containment to avoid environmental contamination.

OSHA Label:

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 1, Subdivision B
Class D, Division 2, Subdivision B

Sucralose
Australia (AICS): Present
EU EINECS/ELINCS List: 259-952-2

Water
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>REACH - Annex IV - Exemptions from the obligations of Register:</th>
<th>Present</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-791-2</td>
</tr>
</tbody>
</table>

Propylene glycol

<table>
<thead>
<tr>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>200-338-0</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.
R41 - Risk of serious damage to eyes.
R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet